Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 17/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388249 | 0.91 | HIF1A (0.64) | HIF1AEGLN1 | |
| SCHEMBL2386090 | 0.90 | HIF1A (0.80) | HIF1AEGLN1 | |
| SCHEMBL12254416 | 0.88 | HIF1A (0.69) | HIF1AEGLN1GSK3B | |
| SCHEMBL2385442 | 0.87 | EGLN1 (0.60) | HIF1AEGLN1 | |
| SCHEMBL2385383 | 0.86 | EGLN1 (0.79) | HIF1AEGLN1 | |
| SCHEMBL2382556 | 0.86 | HIF1A (0.66) | HIF1AEGLN1 | |
| SCHEMBL2383785 | 0.84 | EGLN1 (0.57) | HIF1AEGLN1 | |
| SCHEMBL2396398 | 0.84 | EGLN1 (0.57) | HIF1AEGLN1 | |
| SCHEMBL2386048 | 0.84 | HIF1A (0.62) | HIF1AEGLN1 | |
| SCHEMBL2384134 | 0.83 | KMT2A (0.70) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | claimed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | claimed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | HIF1A 4/4885EGLN1 6/4885GSK3B 1240/4885 |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | HIF1A 4/4885EGLN1 6/4885GSK3B 1351/4885 |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | EGLN3, HIF1AN, EGLN2 | HIF1A 4/4885EGLN1 6/4885GSK3B 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.